You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希诺及药明系股份倒跌8%-8.6% 以色列数据确认辉瑞疫苗保护力高
阿思达克 02-22 15:56
以色列研究数据显示接种两剂辉瑞/BioNTech新冠疫苗後感染风险大降95.8%,医药股今天普遍下滑,尤其是药明生物(02269.HK)继上周二升至128.9元纪录高遇阻掉头向下,最近五个月交易日仅上周五反弹,其余均跌兼已失守10天及20天线,今天股价低见107元,现造108元,急挫7.9%;非蓝筹药明康德(02359.HK)也由高位203元,掉头倒跌8.1%报183.1元。

同为蓝筹石药(01093.HK)及中生制药(01177.HK)今早高开见8.8元7.75元遇阻,掉头倒跌3.1%及2.8%,报8.37元及7.42元,後者股价一举失守50天、20天及10天线。

康希诺生物(06185.HK)由高位三连跌,报350.8元,挫8.6%。信达生物(01801.HK)反覆跌6.1%报87元。微创医疗(00853.HK)倒跌6.9%报47.8元,股价失守50天线(49.3元)。复星医药(02196.HK)由高位六连跌,报37.8元,反覆续跌2.8%。威高股份(01066.HK)反覆续跌5.5%报14.08元。

相反,三生制药(01530.HK)五连涨,承上周五升破牛熊线(8.62元)势,今天高见9.33元,创逾五个月高,现造9.01元,续升2.7%。四环医药(00460.HK)由逾三年高位掉头三连吐守稳10天线,今天股价高见2.85元,暂受制上周所创高位2.91元,现造2.75元,回升5%。神威药业(02877.HK)升4.2%曾高见6.05元创逾11个月高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account